Nature Communications (May 2017)
A promoter-proximal transcript targeted by genetic polymorphism controls E-cadherin silencing in human cancers
- Giuseppina Pisignano,
- Sara Napoli,
- Marco Magistri,
- Sarah N. Mapelli,
- Chiara Pastori,
- Stefano Di Marco,
- Gianluca Civenni,
- Domenico Albino,
- Claudia Enriquez,
- Sara Allegrini,
- Abhishek Mitra,
- Gioacchino D’Ambrosio,
- Maurizia Mello-Grand,
- Giovanna Chiorino,
- Ramon Garcia-Escudero,
- Gabriele Varani,
- Giuseppina M. Carbone,
- Carlo V. Catapano
Affiliations
- Giuseppina Pisignano
- Tumor Biology and Experimental Therapeutics Program, Institute of Oncology Research (IOR), and Oncology Institute of Southern Switzerland (IOSI)
- Sara Napoli
- Tumor Biology and Experimental Therapeutics Program, Institute of Oncology Research (IOR), and Oncology Institute of Southern Switzerland (IOSI)
- Marco Magistri
- Tumor Biology and Experimental Therapeutics Program, Institute of Oncology Research (IOR), and Oncology Institute of Southern Switzerland (IOSI)
- Sarah N. Mapelli
- Tumor Biology and Experimental Therapeutics Program, Institute of Oncology Research (IOR), and Oncology Institute of Southern Switzerland (IOSI)
- Chiara Pastori
- Tumor Biology and Experimental Therapeutics Program, Institute of Oncology Research (IOR), and Oncology Institute of Southern Switzerland (IOSI)
- Stefano Di Marco
- Tumor Biology and Experimental Therapeutics Program, Institute of Oncology Research (IOR), and Oncology Institute of Southern Switzerland (IOSI)
- Gianluca Civenni
- Tumor Biology and Experimental Therapeutics Program, Institute of Oncology Research (IOR), and Oncology Institute of Southern Switzerland (IOSI)
- Domenico Albino
- Tumor Biology and Experimental Therapeutics Program, Institute of Oncology Research (IOR), and Oncology Institute of Southern Switzerland (IOSI)
- Claudia Enriquez
- Tumor Biology and Experimental Therapeutics Program, Institute of Oncology Research (IOR), and Oncology Institute of Southern Switzerland (IOSI)
- Sara Allegrini
- Tumor Biology and Experimental Therapeutics Program, Institute of Oncology Research (IOR), and Oncology Institute of Southern Switzerland (IOSI)
- Abhishek Mitra
- Tumor Biology and Experimental Therapeutics Program, Institute of Oncology Research (IOR), and Oncology Institute of Southern Switzerland (IOSI)
- Gioacchino D’Ambrosio
- IRCCS Multimedica
- Maurizia Mello-Grand
- Laboratory of Cancer Genomics, Fondo Edo Tempia
- Giovanna Chiorino
- Laboratory of Cancer Genomics, Fondo Edo Tempia
- Ramon Garcia-Escudero
- Tumor Biology and Experimental Therapeutics Program, Institute of Oncology Research (IOR), and Oncology Institute of Southern Switzerland (IOSI)
- Gabriele Varani
- Department of Chemistry, University of Washington
- Giuseppina M. Carbone
- Tumor Biology and Experimental Therapeutics Program, Institute of Oncology Research (IOR), and Oncology Institute of Southern Switzerland (IOSI)
- Carlo V. Catapano
- Tumor Biology and Experimental Therapeutics Program, Institute of Oncology Research (IOR), and Oncology Institute of Southern Switzerland (IOSI)
- DOI
- https://doi.org/10.1038/ncomms15622
- Journal volume & issue
-
Vol. 8,
no. 1
pp. 1 – 16
Abstract
Promoter-proximal transcripts have been proposed to act ascis-acting elements regulating transcription. Here, the authors provide evidence that a promoter-proximal RNA, in combination with other epigenetic regulators, controls transcription of E-cadherin in epithelial cancers.
